Physician profile
Jeff D Miller
NPI 1154323632
$2,369.56
in general payments reported to CMS, 2019-2025
18 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $855 · 2021: $138 · 2022: $383 · 2023: $348 · 2024: $249 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $700.31 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $324.22 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $220.20 | 2019-2025 | Total30, Simbrinza |
| Sun Pharmaceutical Industries INC. | $216.51 | 2020-2025 | |
| Abbvie INC. | $182.99 | 2022-2025 | |
| Biotissue Holdings INC. | $144.06 | 2023 | |
| Sight Sciences, INC. | $116.33 | 2022 | |
| Bausch & Lomb Americas INC. | $102.77 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.16 | 2019-2021 | |
| Shire North American Group INC | $63.91 | 2019 | |
| Dompe US, INC. | $46.05 | 2025 | Oxervate |
| Coopervision INC. | $40.47 | 2020-2023 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $38.88 | 2024-2025 | Xdemvy |
| Allergan, INC. | $21.86 | 2021 | |
| Tearlab Corp | $19.30 | 2024 | Scoutpro Osmolarity System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.81 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.95 | 2019 | |
| Oyster Point Pharma, INC. | $12.78 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.